c-kit+ cells

Phase 2Biologic

TThe University of Texas Health Science Center, Houston

c-kit+ cells is one of 31 biologic programs targeting Hypoplastic Left Heart Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypoplastic Left Heart SyndromeActive, not recruiting

Heart FailureActive, not recruiting

Hypoplastic Left Heart SyndromePhase 1

Active, not recruiting

Heart FailurePhase 2

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Brethine

Sanofi

Preclinical

1 2

Amidate

Pfizer

Preclinical

1 3

LCZ696

Novartis

Preclinical

15 4

Activase

Roche

Preclinical

—5

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 6

Zoloft

VViatris Specialty LLC

Preclinical

2 7

c-kit+ cells

TThe University of Texas Health Science Center, Houston

Phase 2

1 8

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 9

Kuvan

BioMarin Pharmaceutical

Preclinical

1 10

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heart Failure1 trial

Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

Completed·TThe University of Texas Health Science Center, Houston·Phase 2·NCT02501811·125 enrolled

Hypoplastic Left Heart Syndrome1 trial

The CHILD Trial: Hypoplastic Left Heart Syndrome Study.

Completed·JJoshua M Hare·Phase 1·NCT03406884·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for c-kit+ cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — c-kit+ cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for c-kit+ cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Texas Health Science Center, Houston company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: TThe University of Texas Health Science Center, Houston

c-kit+ cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Heart Failure1 trial

Hypoplastic Left Heart Syndrome1 trial

References

Drug Info

Quick Facts

Related News